Join Growin Stock Community!

Guardant health, inc.GH.US Overview

US StockHealthcare
(No presentation for GH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GH AI Insights

GH Overall Performance

GH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GH Recent Performance

-2.19%

Guardant health, inc.

0.05%

Avg of Sector

-0.31%

S&P500

GH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GH Key Information

GH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GH Profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Price of GH

GH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.17
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.54
PB Ratio
55.67
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.46%
Net Margin
-42.39%
Revenue Growth (YoY)
32.88%
Profit Growth (YoY)
40.91%
3-Year Revenue Growth
30.39%
3-Year Profit Growth
31.59%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.17
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.54
PB Ratio
55.67
Price-to-FCF
-
Gross Margin
64.46%
Net Margin
-42.39%
Revenue Growth (YoY)
32.88%
Profit Growth (YoY)
40.91%
3-Year Revenue Growth
30.39%
3-Year Profit Growth
31.59%

  • When is GH's latest earnings report released?

    The most recent financial report for Guardant health, inc. (GH) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GH's short-term business performance and financial health. For the latest updates on GH's earnings releases, visit this page regularly.

  • What is the operating profit of GH?

    According to the latest financial report, Guardant health, inc. (GH) reported an Operating Profit of -120.81M with an Operating Margin of -42.95% this period, representing a growth of 4.1% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is GH's revenue growth?

    In the latest financial report, Guardant health, inc. (GH) announced revenue of 281.27M, with a Year-Over-Year growth rate of 39.37%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does GH have?

    At the end of the period, Guardant health, inc. (GH) held Total Cash and Cash Equivalents of 489.42M, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does GH go with three margins increasing?

    In the latest report, Guardant health, inc. (GH) did not achieve the “three margins increasing” benchmark, with a gross margin of 64.6%%, operating margin of -42.95%%, and net margin of -45.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GH's profit trajectory and future growth potential.

  • Is GH's EPS continuing to grow?

    According to the past four quarterly reports, Guardant health, inc. (GH)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GH?

    Guardant health, inc. (GH)'s Free Cash Flow (FCF) for the period is -54.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 34.98% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GH?

    The latest valuation data shows Guardant health, inc. (GH) has a Price-To-Earnings (PE) ratio of -33.52 and a Price/Earnings-To-Growth (PEG) ratio of -0.73. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.